A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

1. Martínez-Cuadrón, D.
2. Boluda, B.
3. Martínez, P.
4. Bergua, J.
5. Rodríguez-Veiga, R.
6. Esteve, J.
7. Vives, S.
8. Serrano, J.
9. Vidriales, B.
10. Salamero, O.
11. Cordón, L.
12. Sempere, A.
13. Jiménez-Ubieto, A.
14. Prieto-Delgado, J.
15. Díaz-Beyá, M.
16. Garrido, A.
17. Benavente, C.
18. Pérez-Simón, J.A.
19. Moscardó, F.
20. Sanz, M.A.
21. Montesinos, P.